
Benzinga Pro data, Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $25.26 million. Earnings fell to a loss of $64.34 million, resulting in a 1.97% decrease from last quarter. In Q4, Revance Therapeutics brought in $25.95 million in sales but lost $63.10 million in earnings.